Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 269

1.

Discriminative T cell recognition of cross-reactive islet-antigens is associated with HLA-DQ8 transdimer-mediated autoimmune diabetes.

Chow IT, Gates TJ, Papadopoulos GK, Moustakas AK, Kolawole EM, Notturno RJ, McGinty JW, Torres-Chinn N, James EA, Greenbaum C, Nepom GT, Evavold BD, Kwok WW.

Sci Adv. 2019 Aug 21;5(8):eaaw9336. doi: 10.1126/sciadv.aaw9336. eCollection 2019 Aug.

2.

The MALT1 locus and peanut avoidance in the risk for peanut allergy.

Winters A, Bahnson HT, Ruczinski I, Boorgula MP, Malley C, Keramati AR, Chavan S, Larson D, Cerosaletti K, Sayre PH, Plaut M, Du Toit G, Lack G, Barnes KC, Nepom GT, Mathias RA; Immune Tolerance Network LEAP Study Team.

J Allergy Clin Immunol. 2019 Jun;143(6):2326-2329. doi: 10.1016/j.jaci.2019.02.016. Epub 2019 Feb 27. No abstract available.

3.

Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance.

Glatigny S, Höllbacher B, Motley SJ, Tan C, Hundhausen C, Buckner JH, Smilek D, Khoury SJ, Ding L, Qin T, Pardo J, Nepom GT, Turka LA, Harris KM, Campbell DJ, Bettelli E.

J Immunol. 2019 Mar 1;202(5):1373-1382. doi: 10.4049/jimmunol.1801425. Epub 2019 Jan 25.

PMID:
30683697
4.

Synchronous immune alterations mirror clinical response during allergen immunotherapy.

Renand A, Shamji MH, Harris KM, Qin T, Wambre E, Scadding GW, Wurtzen PA, Till SJ, Togias A, Nepom GT, Kwok WW, Durham SR.

J Allergy Clin Immunol. 2018 May;141(5):1750-1760.e1. doi: 10.1016/j.jaci.2017.09.041. Epub 2017 Nov 9.

5.

Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.

Long SA, Thorpe J, Herold KC, Ehlers M, Sanda S, Lim N, Linsley PS, Nepom GT, Harris KM.

Cell Immunol. 2017 Sep;319:3-9. doi: 10.1016/j.cellimm.2017.07.007. Epub 2017 Aug 18.

6.

Looking behind the data curtain.

Nepom GT, Scott D.

Cell Immunol. 2017 Sep;319:1-2. doi: 10.1016/j.cellimm.2017.07.008. Epub 2017 Jul 22. No abstract available.

PMID:
28754194
7.

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.

Long SA, Thorpe J, DeBerg HA, Gersuk V, Eddy J, Harris KM, Ehlers M, Herold KC, Nepom GT, Linsley PS.

Sci Immunol. 2016 Nov;1(5). pii: eaai7793. doi: 10.1126/sciimmunol.aai7793. Epub 2016 Nov 18.

8.

Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4+ T Cells in Peripheral Blood of Subjects with Type 1 Diabetes.

Cerosaletti K, Barahmand-Pour-Whitman F, Yang J, DeBerg HA, Dufort MJ, Murray SA, Israelsson E, Speake C, Gersuk VH, Eddy JA, Reijonen H, Greenbaum CJ, Kwok WW, Wambre E, Prlic M, Gottardo R, Nepom GT, Linsley PS.

J Immunol. 2017 Jul 1;199(1):323-335. doi: 10.4049/jimmunol.1700172. Epub 2017 May 31.

9.

Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to β Cell Antigens Are Focused on a Unique Set of Epitopes.

Yang J, Wen X, Xu H, Torres-Chinn N, Speake C, Greenbaum CJ, Nepom GT, Kwok WW.

J Immunol. 2017 Jul 1;199(1):91-96. doi: 10.4049/jimmunol.1601570. Epub 2017 May 26.

10.

Academic, Foundation, and Industry Collaboration in Finding New Therapies.

Ramsey BW, Nepom GT, Lonial S.

N Engl J Med. 2017 May 4;376(18):1762-1769. doi: 10.1056/NEJMra1612575. Review. No abstract available.

11.

Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity.

Bonifacio E, Mathieu C, Nepom GT, Ziegler AG, Anhalt H, Haller MJ, Harrison LC, Hebrok M, Kushner JA, Norris JM, Peakman M, Powers AC, Todd JA, Atkinson MA.

Diabetologia. 2017 Jan;60(1):35-38. Epub 2016 Oct 26.

12.

Clinical trial data access: Opening doors with TrialShare.

Asare AL, Carey VJ, Rotrosen D, Nepom GT.

J Allergy Clin Immunol. 2016 Sep;138(3):724-726. doi: 10.1016/j.jaci.2016.05.034. Epub 2016 Jul 12. No abstract available.

PMID:
27474121
13.

Correlation Among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation After Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial.

Pinckney A, Rigby MR, Keyes-Elstein L, Soppe CL, Nepom GT, Ehlers MR.

Clin Ther. 2016 Jun;38(6):1327-1339. doi: 10.1016/j.clinthera.2016.04.032. Epub 2016 May 18.

14.

Genetically modified human CD4(+) T cells can be evaluated in vivo without lethal graft-versus-host disease.

Ali R, Babad J, Follenzi A, Gebe JA, Brehm MA, Nepom GT, Shultz LD, Greiner DL, DiLorenzo TP.

Immunology. 2016 Aug;148(4):339-51. doi: 10.1111/imm.12613.

15.

Obstacles and opportunities for targeting the effector T cell response in type 1 diabetes.

Buckner JH, Nepom GT.

J Autoimmun. 2016 Jul;71:44-50. doi: 10.1016/j.jaut.2016.02.009. Epub 2016 Mar 3. Review.

16.

A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.

Gill RG, Pagni PP, Kupfer T, Wasserfall CH, Deng S, Posgai A, Manenkova Y, Bel Hani A, Straub L, Bernstein P, Atkinson MA, Herold KC, von Herrath M, Staeva T, Ehlers MR, Nepom GT.

Diabetes. 2016 May;65(5):1310-6. doi: 10.2337/db15-0492. Epub 2015 Dec 30.

17.

Adult-onset type 1 diabetes patients display decreased IGRP-specific Tr1 cells in blood.

Chujo D, Nguyen TS, Foucat E, Blankenship D, Banchereau J, Nepom GT, Chaussabel D, Ueno H.

Clin Immunol. 2015 Dec;161(2):270-7. doi: 10.1016/j.clim.2015.08.014. Epub 2015 Sep 2.

PMID:
26341315
18.

Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.

Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR.

J Clin Invest. 2015 Aug 3;125(8):3285-96. doi: 10.1172/JCI81722. Epub 2015 Jul 20.

19.

Biomarkers for antigen immunotherapy in allergy and type 1 diabetes.

Odegard JM, Nepom GT, Wambre E.

Clin Immunol. 2015 Nov;161(1):44-50. doi: 10.1016/j.clim.2015.05.023. Epub 2015 Jun 27. Review.

20.

Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis.

Cao Y, Goods BA, Raddassi K, Nepom GT, Kwok WW, Love JC, Hafler DA.

Sci Transl Med. 2015 May 13;7(287):287ra74. doi: 10.1126/scitranslmed.aaa8038.

21.

Avidity-dependent programming of autoreactive T cells in T1D.

Durinovic-Belló I, Gersuk VH, Ni C, Wu R, Thorpe J, Jospe N, Sanda S, Greenbaum CJ, Nepom GT.

PLoS One. 2014 May 20;9(5):e98074. doi: 10.1371/journal.pone.0098074. eCollection 2014.

22.

Restoring the balance: immunotherapeutic combinations for autoimmune disease.

Smilek DE, Ehlers MR, Nepom GT.

Dis Model Mech. 2014 May;7(5):503-13. doi: 10.1242/dmm.015099. Review.

23.

Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.

Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team.

Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94. doi: 10.1016/S2213-8587(13)70111-6. Epub 2013 Sep 23.

24.

Low HERV-K(C4) copy number is associated with type 1 diabetes.

Mason MJ, Speake C, Gersuk VH, Nguyen QA, O'Brien KK, Odegard JM, Buckner JH, Greenbaum CJ, Chaussabel D, Nepom GT.

Diabetes. 2014 May;63(5):1789-95. doi: 10.2337/db13-1382. Epub 2014 Jan 15.

25.

Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.

Dahan R, Gebe JA, Preisinger A, James EA, Tendler M, Nepom GT, Reiter Y.

J Autoimmun. 2013 Dec;47:83-93. doi: 10.1016/j.jaut.2013.08.009. Epub 2013 Oct 3.

PMID:
24090977
26.

IL-10 induction from implants delivering pancreatic islets and hyaluronan.

Bollyky PL, Vernon RB, Falk BA, Preisinger A, Gooden MD, Nepom GT, Gebe JA.

J Diabetes Res. 2013;2013:342479. doi: 10.1155/2013/342479. Epub 2013 Jul 22.

27.

Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines.

Obermoser G, Presnell S, Domico K, Xu H, Wang Y, Anguiano E, Thompson-Snipes L, Ranganathan R, Zeitner B, Bjork A, Anderson D, Speake C, Ruchaud E, Skinner J, Alsina L, Sharma M, Dutartre H, Cepika A, Israelsson E, Nguyen P, Nguyen QA, Harrod AC, Zurawski SM, Pascual V, Ueno H, Nepom GT, Quinn C, Blankenship D, Palucka K, Banchereau J, Chaussabel D.

Immunity. 2013 Apr 18;38(4):831-44. doi: 10.1016/j.immuni.2012.12.008.

28.

Anti-cytokine therapies in T1D: Concepts and strategies.

Nepom GT, Ehlers M, Mandrup-Poulsen T.

Clin Immunol. 2013 Dec;149(3):279-85. doi: 10.1016/j.clim.2013.02.003. Epub 2013 Feb 14. Review.

29.

Reversal of diabetes in mice with a bioengineered islet implant incorporating a type I collagen hydrogel and sustained release of vascular endothelial growth factor.

Vernon RB, Preisinger A, Gooden MD, D'Amico LA, Yue BB, Bollyky PL, Kuhr CS, Hefty TR, Nepom GT, Gebe JA.

Cell Transplant. 2012;21(10):2099-110. doi: 10.3727/096368912X636786.

30.

A functional framework for interpretation of genetic associations in T1D.

Nepom GT, Buckner JH.

Curr Opin Immunol. 2012 Oct;24(5):516-21. doi: 10.1016/j.coi.2012.07.003. Epub 2012 Jul 26. Review.

31.

T cell autoreactivity in the transplant milieu.

Matthis J, Nepom GT.

Am J Transplant. 2012 Jul;12(7):1674-81. doi: 10.1111/j.1600-6143.2012.04109.x. Epub 2012 May 29. Review.

32.

MHC class II tetramers.

Nepom GT.

J Immunol. 2012 Mar 15;188(6):2477-82. doi: 10.4049/jimmunol.1102398. Review.

33.

Self-reactive human CD4 T cell clones form unusual immunological synapses.

Schubert DA, Gordo S, Sabatino JJ Jr, Vardhana S, Gagnon E, Sethi DK, Seth NP, Choudhuri K, Reijonen H, Nepom GT, Evavold BD, Dustin ML, Wucherpfennig KW.

J Exp Med. 2012 Feb 13;209(2):335-52. doi: 10.1084/jem.20111485. Epub 2012 Feb 6.

34.

Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience.

Ehlers MR, Nepom GT.

Rev Diabet Stud. 2012 Winter;9(4):359-71. doi: 10.1900/RDS.2012.9.359. Epub 2012 Dec 28. Review.

35.

Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration.

Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT, Wight TN.

Matrix Biol. 2012 Mar;31(2):90-100. doi: 10.1016/j.matbio.2011.10.004. Epub 2011 Nov 20.

36.

Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis.

Raddassi K, Kent SC, Yang J, Bourcier K, Bradshaw EM, Seyfert-Margolis V, Nepom GT, Kwok WW, Hafler DA.

J Immunol. 2011 Jul 15;187(2):1039-46. doi: 10.4049/jimmunol.1001543. Epub 2011 Jun 8.

37.

Investigating the role of T-cell avidity and killing efficacy in relation to type 1 diabetes prediction.

Khadra A, Pietropaolo M, Nepom GT, Sherman A.

PLoS One. 2011 May 10;6(5):e14796. doi: 10.1371/journal.pone.0014796.

38.

ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors.

Bollyky PL, Wu RP, Falk BA, Lord JD, Long SA, Preisinger A, Teng B, Holt GE, Standifer NE, Braun KR, Xie CF, Samuels PL, Vernon RB, Gebe JA, Wight TN, Nepom GT.

Proc Natl Acad Sci U S A. 2011 May 10;108(19):7938-43. doi: 10.1073/pnas.1017360108. Epub 2011 Apr 25.

39.

Challenges in the pursuit of immune tolerance.

Nepom GT, St Clair EW, Turka LA.

Immunol Rev. 2011 May;241(1):49-62. doi: 10.1111/j.1600-065X.2011.01003.x. Review.

40.

Common variants in P2RY11 are associated with narcolepsy.

Kornum BR, Kawashima M, Faraco J, Lin L, Rico TJ, Hesselson S, Axtell RC, Kuipers H, Weiner K, Hamacher A, Kassack MU, Han F, Knudsen S, Li J, Dong X, Winkelmann J, Plazzi G, Nevsimalova S, Hong SC, Honda Y, Honda M, Högl B, Ton TG, Montplaisir J, Bourgin P, Kemlink D, Huang YS, Warby S, Einen M, Eshragh JL, Miyagawa T, Desautels A, Ruppert E, Hesla PE, Poli F, Pizza F, Frauscher B, Jeong JH, Lee SP, Strohl KP, Longstreth WT Jr, Kvale M, Dobrovolna M, Ohayon MM, Nepom GT, Wichmann HE, Rouleau GA, Gieger C, Levinson DF, Gejman PV, Meitinger T, Peppard P, Young T, Jennum P, Steinman L, Tokunaga K, Kwok PY, Risch N, Hallmayer J, Mignot E.

Nat Genet. 2011 Jan;43(1):66-71. doi: 10.1038/ng.734. Epub 2010 Dec 19. Erratum in: Nat Genet. 2011 Oct;43(10):1040.

41.

The Immune Tolerance Network at 10 years: tolerance research at the bedside.

Bluestone JA, Auchincloss H, Nepom GT, Rotrosen D, St Clair EW, Turka LA.

Nat Rev Immunol. 2010 Nov;10(11):797-803. doi: 10.1038/nri2869. Review.

PMID:
20972473
42.

A functional RANKL polymorphism associated with younger age at onset of rheumatoid arthritis.

Tan W, Wu H, Zhao J, Derber LA, Lee DM, Shadick NA, Conn DL, Smith EA, Gersuk VH, Nepom GT, Moreland LW, Furst DE, Thompson SD, Jonas BL, Holers VM, Glass DN, Chen PP, Bridges SL Jr, Weinblatt ME, Paulus HE, Tsao BP.

Arthritis Rheum. 2010 Oct;62(10):2864-75. doi: 10.1002/art.27589.

43.

Prediction and pathogenesis in type 1 diabetes.

Ziegler AG, Nepom GT.

Immunity. 2010 Apr 23;32(4):468-78. doi: 10.1016/j.immuni.2010.03.018. Review.

44.

Th1 cytokines promote T-cell binding to antigen-presenting cells via enhanced hyaluronan production and accumulation at the immune synapse.

Bollyky PL, Evanko SP, Wu RP, Potter-Perigo S, Long SA, Kinsella B, Reijonen H, Guebtner K, Teng B, Chan CK, Braun KR, Gebe JA, Nepom GT, Wight TN.

Cell Mol Immunol. 2010 May;7(3):211-20. doi: 10.1038/cmi.2010.9. Epub 2010 Mar 15.

45.

Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells.

Vendrame F, Pileggi A, Laughlin E, Allende G, Martin-Pagola A, Molano RD, Diamantopoulos S, Standifer N, Geubtner K, Falk BA, Ichii H, Takahashi H, Snowhite I, Chen Z, Mendez A, Chen L, Sageshima J, Ruiz P, Ciancio G, Ricordi C, Reijonen H, Nepom GT, Burke GW 3rd, Pugliese A.

Diabetes. 2010 Apr;59(4):947-57. doi: 10.2337/db09-0498. Epub 2010 Jan 19.

46.

Insulin gene VNTR genotype associates with frequency and phenotype of the autoimmune response to proinsulin.

Durinovic-Belló I, Wu RP, Gersuk VH, Sanda S, Shilling HG, Nepom GT.

Genes Immun. 2010 Mar;11(2):188-93. doi: 10.1038/gene.2009.108. Epub 2010 Jan 7.

47.

On-chip activation and subsequent detection of individual antigen-specific T cells.

Song Q, Han Q, Bradshaw EM, Kent SC, Raddassi K, Nilsson B, Nepom GT, Hafler DA, Love JC.

Anal Chem. 2010 Jan 15;82(2):473-7. doi: 10.1021/ac9024363.

48.

Remodeling rodent models to mimic human type 1 diabetes.

von Herrath M, Nepom GT.

Eur J Immunol. 2009 Aug;39(8):2049-54. doi: 10.1002/eji.200939429.

49.

CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta.

Bollyky PL, Falk BA, Long SA, Preisinger A, Braun KR, Wu RP, Evanko SP, Buckner JH, Wight TN, Nepom GT.

J Immunol. 2009 Aug 15;183(4):2232-41. doi: 10.4049/jimmunol.0900191. Epub 2009 Jul 27.

50.

Restricted autoantigen recognition associated with deletional and adaptive regulatory mechanisms.

Gebe JA, Yue BB, Unrath KA, Falk BA, Nepom GT.

J Immunol. 2009 Jul 1;183(1):59-65. doi: 10.4049/jimmunol.0804046. Epub 2009 Jun 17.

Supplemental Content

Loading ...
Support Center